| 000 | 03357naa a22005177i 4500 | ||
|---|---|---|---|
| 001 | UMUN-OA-20261005-MLS-052 | ||
| 003 | local | ||
| 005 | 20261005174905.0 | ||
| 006 | m o d | ||
| 007 | cr|||||||||||| | ||
| 008 | 261005s2020 xx o u000 0 eng d | ||
| 024 | 7 |
_a10.1186/s12931-020-01570-2 _2doi |
|
| 035 | _a(local)EuropePMC:PMC7677848 | ||
| 040 |
_alocal _beng _clocal |
||
| 041 | 0 | _aeng | |
| 100 | 0 |
_aGrégoire Ruffenach _eauthor. |
|
| 245 | 1 | 0 |
_aPulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights. / _cGrégoire Ruffenach; Jason Hong; Mylène Vaillancourt [and others]. |
| 264 | 1 |
_a[Place of publication not identified] : _bBMC, _c2020. |
|
| 300 | _a1 online resource (1 article). | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 500 | _aPublication type: Review article. | ||
| 500 | _aLinked open-access copy: published version. | ||
| 506 | 0 |
_aOpen access; no subscription required for the linked open-access version. _fUnrestricted online access _2star |
|
| 520 | 3 | _aPulmonary hypertension (PH) developing secondarily in pulmonary fibrosis (PF) patients (PF-PH) is a frequent co-morbidity. The high prevalence of PH in PF patients is very concerning since the presence of PH is a strong predictor of mortality in PF patients. Until recently, PH was thought to arise solely from fibrotic destruction of the lung parenchyma, leading to hypoxic vasoconstriction and loss of vascular bed density. Thus, potential cellular and molecular dysregulation of vascular remodeling as a driver of PF-PH has been under-investigated. The recent demonstrations that there is no correlation between the severity of the fibrosis and development of PH, along with the finding that significant vascular histological and molecular differences exist between patients with and without PH have shifted the etiological paradigm of PF-PH. This review aims to provide a comprehensive translational overview of PH in PF patients from clinical diagnosis and outcome to the latest understanding of the histology and molecular pathophysiology of PF-PH. | |
| 540 |
_aCreative Commons Attribution. See the linked licence for the applicable terms. _uhttp://creativecommons.org/licenses/by/4.0/ |
||
| 546 | _aIn English. | ||
| 588 | 0 | _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. | |
| 590 | _aCourse allocation: B. Sc. Medical Laboratory Science. | ||
| 650 | 4 | _aPulmonary fibrosis | |
| 650 | 4 | _aPulmonary hypertension | |
| 650 | 4 | _aVascular diseases | |
| 653 | _aB. Sc. Medical Laboratory Science | ||
| 653 | _aUMUN open access collection | ||
| 653 | _ahistopathology | ||
| 655 | 4 | _aReview articles. | |
| 700 | 0 |
_aJason Hong _eauthor. |
|
| 700 | 0 |
_aMylène Vaillancourt _eauthor. |
|
| 700 | 0 |
_aLejla Medzikovic _eauthor. |
|
| 700 | 0 |
_aMansoureh Eghbali _eauthor. |
|
| 773 | 0 |
_tRespiratory research _gVol. 21, no. 1, (2020), pages/article 303 _x1465-9921 |
|
| 856 | 4 | 0 |
_uhttps://europepmc.org/articles/PMC7677848 _yRead open-access publication _zOpen access. _70 |
| 884 |
_aCourse selection and automated MARC21 enrichment from Europe PMC metadata. _g20261005 _khttps://europepmc.org/articles/PMC7677848 _qlocal |
||
| 942 | _n0 | ||
| 999 |
_c1194 _d1194 |
||